Integer Holdings (ITGR) AI Stock Analysis

• Market Cap: $2.38B
• Dividend Yield: N/A
• Average Volume (3M): 1.12M
• Price to Earnings (P/E): 28.5
• Beta (1Y): 0.60
• Revenue Growth: 7.81%
• EPS Growth: -26.32%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.79
• Shares Outstanding: 35,038,425
• 10 Day Avg. Volume: 2,444,691
• 30 Day Avg. Volume: 1,116,694
• PEG Ratio: 1.15
• Price to Book (P/B): 2.75
• Price to Sales (P/S): 2.59
• P/FCF Ratio: 44.71
• Enterprise Value/Market Cap: 2.04
• Enterprise Value/Revenue: 2.66
• Enterprise Value/Gross Profit: 9.88
• Enterprise Value/Ebitda: 17.02
• 1Y Price Target: $92.75
• Price Target Upside: 42.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 63 Neutral
• Price Target: $70.00 ▲(7.20% Upside)

Integer Holdings' overall stock score reflects strong financial performance and cash flow generation, but is tempered by bearish technical indicators and valuation concerns. The recent earnings call highlighted both strong past performance and future challenges, impacting the outlook.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Cash Flow Generation

Strong cash flow growth enhances financial flexibility, enabling strategic investments and debt reduction, supporting sustainable operations.

Product Development Pipeline

A robust product pipeline positions the company for future growth by introducing innovative solutions and capturing market share.

Negative Factors

Profitability Margins

Declining profit margins indicate rising operational costs, which could pressure long-term profitability if not managed effectively.

New Product Adoption Challenges

Challenges in new product adoption may hinder revenue growth and market penetration, impacting future sales performance.

Market Exit Impact

Exiting a market segment could reduce revenue streams and limit diversification, affecting overall sales and growth potential.

Integer Holdings Business Overview & Revenue Model

Company Description

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

How the Company Makes Money

Integer Holdings generates revenue through the sale of its medical devices and implants across various healthcare sectors. Its primary revenue streams include direct sales of cardiac and neuromodulation devices, orthopedic implants, and related accessories. The company often partners with healthcare providers, hospitals, and distributors to expand its market reach. Additionally, Integer invests in research and development to innovate and improve its product offerings, which helps to maintain a competitive edge and secure long-term contracts with healthcare organizations. Moreover, strategic collaborations and acquisitions within the medical device market further bolster its revenue potential.

Integer Holdings Financial Statement Overview

Summary

Integer Holdings shows steady revenue growth and strong cash flow generation. However, challenges in maintaining profitability margins and increased leverage are concerns. Continued focus on cost management and debt reduction could enhance financial stability.

Income Statement

Integer Holdings has demonstrated consistent revenue growth, with a TTM increase of 2.02% and a solid gross profit margin of 26.89%. However, the net profit margin has decreased to 4.75% in the TTM, indicating some pressure on profitability. The EBIT and EBITDA margins have also shown a decline, suggesting increased operational costs or other financial pressures.

Balance Sheet

The company's debt-to-equity ratio of 0.75 in the TTM indicates a moderate level of leverage, which is manageable but has increased compared to previous years. The return on equity has decreased to 5.21%, reflecting a decline in profitability relative to shareholder equity. The equity ratio remains stable, suggesting a balanced approach to financing.

Cash Flow

Integer Holdings has shown strong free cash flow growth of 12.38% in the TTM, indicating improved cash generation capabilities. The operating cash flow to net income ratio is nearly 1, suggesting efficient cash conversion. The free cash flow to net income ratio of 0.91 further highlights robust cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.83B	1.72B	1.60B	1.38B	1.22B	1.07B
Gross Profit	492.43M	459.01M	418.29M	359.01M	336.97M	285.71M
EBITDA	285.99M	310.91M	256.51M	215.40M	215.26M	207.56M
Net Income	86.90M	119.90M	90.65M	66.38M	96.81M	77.26M
Balance Sheet
Total Assets	3.40B	3.08B	2.94B	2.79B	2.58B	2.37B
Cash, Cash Equivalents and Short-Term Investments	58.94M	46.54M	23.67M	24.27M	17.89M	49.21M
Total Debt	1.31B	1.10B	1.05B	1.01B	897.75M	777.55M
Total Liabilities	1.65B	1.46B	1.42B	1.38B	1.23B	1.10B
Stockholders Equity	1.75B	1.62B	1.52B	1.42B	1.35B	1.27B
Cash Flow
Free Cash Flow	184.87M	99.60M	60.27M	41.65M	103.20M	129.90M
Operating Cash Flow	203.96M	205.21M	180.21M	116.38M	156.67M	181.34M
Investing Cash Flow	-205.65M	-195.41M	-163.37M	-200.42M	-271.00M	-56.58M
Financing Cash Flow	22.97M	13.32M	-18.01M	92.48M	81.99M	-88.58M

Integer Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 65.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITGR, the sentiment is Negative. The current price of 65.3 is below the 20-day moving average (MA) of 95.98, below the 50-day MA of 101.29, and below the 200-day MA of 116.54, indicating a bearish trend. The MACD of -8.59 indicates Positive momentum. The RSI at 16.52 is Positive, neither overbought nor oversold. The STOCH value of 4.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ITGR.

Integer Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TMDX	―	$4.42B	67.08	28.21%	―	48.09%	2410.18%
INSP	―	$2.22B	43.55	8.07%	―	22.05%	785.52%
ITGR	―	$2.38B	28.47	5.18%	―	7.81%	-26.32%
LIVN	―	$2.91B	-13.70	-17.87%	―	8.57%	-1154.64%
ATEC	―	$2.44B	-14.53	-376.89%	―	26.27%	15.58%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GKOS	―	$4.46B	―	-12.98%	―	26.70%	48.19%

Integer Holdings Corporate Events

Integer Holdings Navigates Growth and Challenges in Q3 2025

Integer Holdings Corporation’s recent earnings call presented a mixed sentiment, highlighting strong performance in the third quarter of 2025 and notable growth over the past three years. However, the company also faces challenges with a reduced financial outlook for 2025 and potential difficulties in new product adoption for 2026. Despite these concerns, Integer maintains a robust cash flow and anticipates recovery by 2027, although immediate prospects are affected by changes in customer forecasts and market exit strategies.

Integer Holdings Appoints Payman Khales as New CEO

On October 24, 2025, Integer Holdings Corporation announced the completion of its planned leadership transition with Payman Khales assuming the roles of President and CEO, succeeding Joseph Dziedzic. Mr. Khales, who joined Integer in 2018, has been instrumental in driving growth and improving service levels in his previous roles, and his appointment is expected to continue advancing the company’s strategic goals and strengthen its position as a strategic partner in the medical device industry.

The most recent analyst rating on (ITGR) stock is a Buy with a $77.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.

Integer Holdings Reports Strong Q3 2025 Growth

Integer Holdings Corporation is a leading medical device contract development and manufacturing organization, specializing in cardiac rhythm management, neuromodulation, and cardio and vascular markets. The company is known for its strategic partnerships with medical device companies and OEMs, providing innovative and high-quality products and solutions.

Integer Holdings Reports Strong Q3 2025 Sales Growth

Integer Holdings Corporation reported an 8% increase in sales for the third quarter of 2025, with significant growth in cardio and vascular sales driven by new product introductions and acquisitions. Despite a decrease in GAAP operating income, the company achieved a 14% rise in non-GAAP adjusted operating income and a 25% increase in adjusted EPS. Integer anticipates challenges in 2026 but expects a return to above-market growth by 2027, supported by its robust product development pipeline.

The most recent analyst rating on (ITGR) stock is a Buy with a $133.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.